Table 2 Comparison of anticancer therapies between groups
variable | TB treatment n (%) | Lung cancer n (%) | P value |
|---|---|---|---|
treatment line of anti-cancer chemotherapy | |||
Adjuvant treatment | 3 (9.7) | 9 (17.6) | 0.056 |
First line | 25 (80.6) | 42 (82.4) | |
Second line or later | 3 (9.7) | 0 (0) | |
Chemotherapy regimen | |||
Single agent | 5 (16.1) | 10 (19.5) | 0.308 |
Gemcitabine | 3 (9.7) | 2 (3.9) | |
Pemetrexed | 1 (3.2) | 2 (3.9) | |
Etoposide | 0 | 4 (7.8) | |
Paclitaxel | 1 (3.2) | 2 (3.9) | |
Two agents | 26 (83.9) | 41 (80.5) | 0.879 |
Gemcitabine plus platinum | 12 (38.7) | 15 (29.4) | |
Pemetrexed plus platinum | 7 (22.6) | 14 (27.5) | |
Etoposide plus platinum | 6 (19.4) | 10 (19.6) | |
Paclitaxel plus platinum | 1 (3.2) | 2 (3.9) | |
Cycles of chemotherapy | 4 (3–6) | 5 (4–6) | 0.923 |
Treatment completion rate | |||
Completion | 27 (87.1) | 47 (92.2) | 0.454 |
Active withdrawal | 4 (12.9) | 4 (7.8) | |
Response | 0.322 | ||
Complete response | 0 (0) | 1 (2.0) | |
Partial response | 2 (6.5) | 4 (7.8) | |
Stable disease | 22 (70.9) | 40 (78.4) | |
Progressive disease | 7 (22.6) | 6 (11.8) | |
Median survival (weeks) | 52 (22–82) | 57 (36–64) | 0.505 |
Non-small cell (stage III/IV) | 52 (26–82) (n = 22) | 48 (32–64) (n = 29) | 0.331 |
Small cell (stage III/IV) | 22 (21–33) (n = 6) | 52 (40–57) (n = 13) | 0.323 |
KPS change | 0.715 | ||
Increase | 2 (6.5) | 10 (19.6) | |
Decrease | 2 (6.5) | 1 (2.0) | |
No change | 27 (87.1) | 40 (78.4) | |